Drug firm Jubilant Life Sciences has received approval from the US health regulator to market generic levofloxacin tablets, used to treat various infections including pneumonia.
The company has received approval from the US Food and Drug Administration (USFDA) to market generic version of Levaquin tablets in strengths of 250 mg and 500 mg in the American market, the firm said in a statement.
The drug is used to treat adults with infections such as pneumonia, bacterial sinusitis, chronic bronchitis, skin and skin structure infections, chronic bacterial prostatitis, urinary tract infections and inhalational anthrax.
As per the IMS data, the total market size for levofloxacin tablets stood at around $28 million per annum.
As of March 31, 2015, Jubilant had a total of 806 filings for formulations of which 368 have been approved in various regions globally.
This includes 72 abbreviated new drug applications (ANDAs) filed in the US, of which 38 have been approved.
Drug firm Jubilant Life Sciences has received approval from the US health regulator to market generic levofloxacin tablets, used to treat various infections including pneumonia.
The company has received approval from the US Food and Drug Administration (USFDA) to market generic version of Levaquin tablets in strengths of 250 mg and 500 mg in the American market, the firm said in a statement.
The drug is used to treat adults with infections such as pneumonia, bacterial sinusitis, chronic bronchitis, skin and skin structure infections, chronic bacterial prostatitis, urinary tract infections and inhalational anthrax.
As per the IMS data, the total market size for levofloxacin tablets stood at around $28 million per annum.
As of March 31, 2015, Jubilant had a total of 806 filings for formulations of which 368 have been approved in various regions globally.
This includes 72 abbreviated new drug applications (ANDAs) filed in the US, of which 38 have been approved.
Drug firm Jubilant Life Sciences has received approval from the US health regulator to market generic levofloxacin tablets, used to treat various infections including pneumonia.
The company has received approval from the US Food and Drug Administration (USFDA) to market generic version of Levaquin tablets in strengths of 250 mg and 500 mg in the American market, the firm said in a statement.
The drug is used to treat adults with infections such as pneumonia, bacterial sinusitis, chronic bronchitis, skin and skin structure infections, chronic bacterial prostatitis, urinary tract infections and inhalational anthrax.
As per the IMS data, the total market size for levofloxacin tablets stood at around $28 million per annum.
As of March 31, 2015, Jubilant had a total of 806 filings for formulations of which 368 have been approved in various regions globally.
This includes 72 abbreviated new drug applications (ANDAs) filed in the US, of which 38 have been approved.
Sign Up with Google
RECOMMENDED FOR YOU
POPULAR
